Phase I evaluation of the combination 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) and dianhydrogalactitol (DAG; NSC-132313) in patients with advanced neoplastic diseases

Med Pediatr Oncol. 1979;7(2):179-80. doi: 10.1002/mpo.2950070212.
No abstract available

MeSH terms

  • Bone Marrow / drug effects
  • Carmustine / administration & dosage*
  • Carmustine / toxicity
  • Dianhydrogalactitol / administration & dosage*
  • Dianhydrogalactitol / toxicity
  • Drug Evaluation
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasms / drug therapy*
  • Sugar Alcohols / administration & dosage*

Substances

  • Sugar Alcohols
  • Dianhydrogalactitol
  • Carmustine